News & Updates

Breast arterial calcification (BAC), as viewed on screening mammograms, may suggest a risk of cardiovascular disease (CVD) in postmenopausal women, a recent US-based study showed.

The addition of toripalimab to first-line chemotherapy led to significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC) without EGFR/ALK mutations, according to the updated results of the CHOICE-01* trial presented at the ASCO Plenary 2022.

Sentinel lymph node (SLN) biopsy for early oral cavity cancer is likely to yield a false negative result when the number of SLNs is small, a recent study has found.

In patients who discontinued a checkpoint inhibitor (CPI) due to severe immune-related hepatitis, retreatment with the same or a different CPI is feasible after resolution of the liver injury and does not lead to recurrence in up to 65 percent of patients, according to a study.

Adding tislelizumab to chemotherapy in the first-line setting sustains progression-free survival (PFS) benefit in patients with recurrent/metastatic nasopharyngeal cancer (R/M NPC), according to updated results of the RATIONALE-309* trial presented at the ASCO Plenary 2022.